Chief Accounting Officer
Fulcrum Therapeutics, Inc. (FULC)Equibles does not estimate personal net worth.
Get an email with a short summary when Fulcrum Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get FULC alertsAlan Musso is recorded as Chief Accounting Officer at Fulcrum Therapeutics, Inc. (FULC) since August 7, 2026 and CFO at Fulcrum Therapeutics, Inc. (FULC). Fulcrum Therapeutics, Inc. reported in an 8-K filed August 10, 2026 that Alan Musso was appointed principal accounting officer, effective August 7, 2026. The proxy statement of Fulcrum Therapeutics, Inc. reports total compensation of $1,807,125 for Alan Musso in fiscal 2025, including a base salary of $478,100. Disclosed compensation is on record for 3 fiscal years. Alan Musso has spoken on 9 earnings calls across 1 company, most recently for Fulcrum Therapeutics, Inc. on April 27, 2026. Fulcrum Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Fulcrum Therapeutics, Inc. includes Alex C. Sapir (CEO and Board Member), Bryan Stuart (CEO, COO and Board Member), Robert J. Gould (CEO) and 7 others.
“on August 9, 2026, Fulcrum's Board of Directors appointed Alan Musso, Fulcrum's chief financial officer and principal financial officer, as principal accounting officer, effective August 7, 2026, upon Mr. Tourangeau's departure.”
“It's been a privilege to be part of Fulcrum's progress and I'm proud of what we've accomplished together. With the impressive results from the Pioneer trial, a talented and motivated team, and a strong capital base, the company is well positioned to deliver transformative therapy for sickle cell patients.”
“I'll now go over our results for the third quarter ended September 30, 2025. Our research and development expenses were $14.3 million for the third quarter of 2025 compared to $14.6 million for the third quarter of 2024.”
“I'll now go over our results for the quarter ended March 31, 2025. Our research and development expenses were $13.4 million for the first quarter of 2025, compared to $19.8 million for the first quarter of 2024.”
“I'll now go over our results for the fourth quarter and for the full year ended December 31, 2024, beginning with results for the quarter. We had no collaboration revenues in the fourth quarter of 2024 compared to $900,000 for the fourth quarter of 2023.”
“I'll now review our financial results, starting with our cash position. As of September 30, 2024, cash, cash equivalents, and marketable securities were $257.2 million compared to $236.2 million as of December 31, 2023.”
2026-08-07–present
Biotechnology · Healthcare
CFO, Chief Accounting Officer
2026-08-07–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Fulcrum Therapeutics, Inc. (FULC) | Chief Financial Officer | $478,100 | $1,807,125 |
| 2024 | Fulcrum Therapeutics, Inc. (FULC) | Chief Financial Officer | $457,500 | $1,251,760 |
| 2023 | Fulcrum Therapeutics, Inc. (FULC) | Chief Financial Officer | $180,682 | $1,879,833 |
